Inovio Biomedical Universal influenza vaccines demonstrate 100% protection against current pandemic A/H1N1 influenza viruses in animal studies. The stock is up 366.22% today +2.71 to $3.45. The CDC anticipates a surges of H1N1 cases starting this fall. Other H1N1 companies are Biocryst Pharm (BCRX) and Novavax ((NVAX).
Net sales for the third quarter of fiscal 2009 totaled $190.5 million as compared to $118.1 million reported in the third quarter of fiscal 2008, representing an increase of 61% over the same quarter last year.
Net income for the third quarter of fiscal 2009 increased 123% to $14.1 million or $0.36 per diluted share, from $6.3 million or $0.16 per diluted share in the third quarter of fiscal 2008.
GMCR reports earnings July 29 after the market closes. I’m interested in the Long August 70 calls and short August 80 calls. It’s a heavily shorted stock and I think this stock has more upside.
Yes the market was up last week but the impressive aspect of last week’s market gains is the resiliency of the Dow and S & P on Friday after weaker than expected earnings reports from Microsoft (MSFT), Amazon.com (AMZN) and American Express (AXP). You figure with the substantial gains in all major indices the past few weeks (Dow, Nasdaq and S&P 500) this would have been a perfect opportunity to lock profits. Friday morning started out red and ended up green.
Earnings that I’m following this coming week 7/27 – 7/31: Visa (V) 7/29 before, Mastercard (MA) 7/30 before, First Solar (FSLR) 7/30 after.
Reports Q2 (Jun) earnings of $1.61 per share, including stock options expense, $0.17 better than the First Call consensus of $1.44; revenues rose 37.4% year/year to $160.7 mln vs the $157.8 mln consensus. Adjusted EBITDA was $76.3 mln for the second quarter of 2009, representing a 38.2% increase from the corresponding period in 2008. Co issues upside guidance for Q3, sees Q3 revs of $184-189 vs. $181.94 mln consensus.
Reports Q4 (Jun) earnings of $0.36 per share, in-line with the First Call consensus of $0.36; revenues fell 17.3% year/year to $13.1 bln vs the $14.37 bln consensus. Microsoft is providing operating expense guidance of $26.6 billion to $26.9 billion, for the full year ending June 30, 2010. “Our business continued to be negatively impacted by weakness in the global PC and server markets,”
Reports Q2 (Jun) earnings of $0.32 per share, in-line with the First Call consensus of $0.32; revenues rose 14.5% year/year to $4.65 bln vs the $4.69 bln consensus. AMZN Q2 gross margin 27.4% vs 23.6% consensus. Co issues in-line guidance for Q3, sees Q3 revs of $4.75-5.25 bln vs. $4.92 bln consensus. Operating income is expected to be between $120 mln and $210 mln, or between 22% decline and 36% growth compared with third quarter 2008. This guidance includes approximately $95 mln for stock-based compensation and amortization of intangible assets, and it assumes, among other things, that no additional business acquisitions or investments are concluded and that there are no further revisions to stock-based compensation estimates… Excluding the $227 mln unfavorable impact from year-over-year changes in foreign exchange rates throughout the quarter, net sales would have grown 20% compared with second quarter 2008. Free cash flow increased 89% to $1.54 bln for the trailing twelve months, compared with $0.82 bln for the trailing twelve months ended June 30, 2008.
AMZN Earnings not impressive ,just meets expectations. A bigger concern is MSFT earnings and the impact on the market tomorrow. (missed revenue)